Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
4.330
-0.060 (-1.37%)
At close: May 9, 2025, 4:00 PM
4.330
0.00 (0.00%)
After-hours: May 9, 2025, 7:59 PM EDT
Recursion Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Recursion Pharmaceuticals stock have an average target of 7.60, with a low estimate of 6.00 and a high estimate of 10. The average target predicts an increase of 75.52% from the current stock price of 4.33.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Recursion Pharmaceuticals stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 2 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $11 → $8 | Strong Buy | Maintains | $11 → $8 | +84.76% | May 6, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $10 → $8 | Hold | Maintains | $10 → $8 | +84.76% | Apr 10, 2025 |
| Needham | Needham | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +154.04% | Apr 8, 2025 |
| Leerink Partners | Leerink Partners | Hold Maintains $7 → $6 | Hold | Maintains | $7 → $6 | +38.57% | Feb 28, 2025 |
| Needham | Needham | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +154.04% | Feb 6, 2025 |
Financial Forecast
Revenue This Year
92.55M
from 58.84M
Increased by 57.30%
Revenue Next Year
140.24M
from 92.55M
Increased by 51.53%
EPS This Year
-1.66
from -1.69
EPS Next Year
-1.42
from -1.66
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 183.8M | 257.6M | 52.2M |
| Avg | 92.6M | 140.2M | 50.7M |
| Low | 27.5M | 35.7M | 48.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 212.3% | 178.4% | -62.8% |
| Avg | 57.3% | 51.5% | -63.8% |
| Low | -53.2% | -61.5% | -65.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.11 | -0.97 | -0.60 |
| Avg | -1.66 | -1.42 | -0.86 |
| Low | -3.04 | -2.55 | -1.10 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.